Marrow Drive for Girl with NHL
9-year-old Anna Organek is a Lowell, Michigan girl recently relapsed with non-Hodgkin's lymphoma. A bone marrow or blood stem cell transplant is the treatment doctors wish to try but a matched donor has to identified. None of Anna's family members are a match.
Anna's mother, Heather Organek, and several of Anna's relatives were at a community blood drive last week where 1500 people turned up to see if they matched. But Anna, whose immune system is weak, stayed home.
Organek's family must raise funds to pay for blood tests, which cost $125 each. Tax-exempt checks can be made payable to the Michigan Community Blood Centers, 1036 Fuller Ave. NE, P.O. Box 1704, Grand Rapids, MI 49501-1704. Write "Anna Organek" in the memo area of the check. Articles
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
